ArticleACS nano2011
Nanoparticle-mediated measurement of target-drug binding in cancer cells.
Article in ACS nano, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.International journal of nanomedicine · 2018Article
- Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cells.Biomaterials science · 2016Article
- Click Chemistry-Mediated Nanosensors for Biochemical Assays.Theranostics · 2016Review
- Microchip-based detection of magnetically labeled cancer biomarkers.Advanced drug delivery reviews · 2014Review
- Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Advanced drug delivery reviews · 2014Review
- Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers.Advanced drug delivery reviews · 2014Review
- Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy.Critical reviews in oncogenesis · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Responses to molecularly targeted therapies can be highly variable and depend on mutations, fluctuations in target protein levels in individual cells, and drug delivery. The ability to rapidly quantitate drug response in cells harvested from patients in a point-of-care setting would have far reaching implications. Capitalizing on recent developments with miniaturized NMR technologies, we have developed a magnetic nanoparticle-based approach to directly measure both target expression and drug binding in scant human cells. The method involves covalent conjugation of the small-molecule drug to a magnetic nanoparticle that is then used as a read-out for target expression and drug-binding affinity. Using poly(ADP-ribose) polymerase (PARP) inhibition as a model system, we developed an approach to distinguish differential expression of PARP in scant cells with excellent correlation to gold standards, the ability to mimic drug pharmacodynamics ex vivo through competitive target-drug binding, and the potential to perform such measurements in clinical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.